Vividion Therapeutics and Bayer Expand Oncology Pipeline with Clinical-Stage WRN Inhibitor

Vividion Therapeutics and Bayer Strengthen Oncology Pipeline with Exclusive Rights to Clinical-Stage WRN Inhibitor VVD-214 Vividion Therapeutics, a clinical-stage biopharmaceutical company and a wholly owned, independently operated subsidiary of Bayer AG, announced today it has obtained exclusive global rights to…

Read MoreVividion Therapeutics and Bayer Expand Oncology Pipeline with Clinical-Stage WRN Inhibitor

CWIEME 2025 WACKER Unveils Conductive Silicone Innovation for Power Plant Generators

ELASTOSIL® N 9189: Electrically Conductive Silicone for Power Plant Generators ELASTOSIL® N 9189 is a one-component, room-temperature vulcanizing (RTV-1) silicone rubber that cures upon exposure to atmospheric humidity, releasing only alcohol during the process. This tin-free formulation offers significant processing…

Read MoreCWIEME 2025 WACKER Unveils Conductive Silicone Innovation for Power Plant Generators

Albemarle Releases 2024 Sustainability Report Highlighting Carbon, Water, and Customer Goals

Albemarle Corporation 2024 Sustainability Report: A Comprehensive Overview Albemarle Corporation a global leader in specialty chemicals and a key player in the supply of essential elements for mobility, energy, connectivity, and health, has published its 2024 Sustainability Report titled “Values-Led,…

Read MoreAlbemarle Releases 2024 Sustainability Report Highlighting Carbon, Water, and Customer Goals

Marketing Authorization Application for Gadoquatrane Submitted in Japan

Marketing Authorization Application for Gadoquatrane Submitted in Japan Bayer has officially submitted a marketing authorization application to Japan’s Ministry of Health, Labour and Welfare (MHLW) for gadoquatrane, its investigational gadolinium-based contrast agent designed for use in magnetic resonance imaging (MRI).…

Read MoreMarketing Authorization Application for Gadoquatrane Submitted in Japan